Srinivas Akkaraju, a director and 10% owner of Kalaris Therapeutics (NASDAQ:KLRS), recently engaged in stock transactions through affiliated investment entities.
On May 20, 2026, Samsara Opportunity Fund, L.P., over which Akkaraju has voting and investment power, purchased 244,300 shares at $4.83 each, totaling $1,179,969. This was a privately negotiated purchase from Samsara BioCapital, L.P.
KLRS trades at $4.92, down from its 52-week high of $11.88 but above its low of $2.14. The stock has returned 73.85% over the past year but declined 41.71% year-to-date.
On the same day, Samsara BioCapital distributed 66,906 shares to Samsara Opportunity Fund. Post-transaction, Samsara Opportunity Fund holds 2,224,147 shares, and Samsara BioCapital holds 10,657,028 shares.
Kalaris has a market cap of $112.2 million and holds more cash than debt. Analysts set price targets between $7 and $25, but the company remains unprofitable.
